We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

821 hedge funds and large institutions have $59.2B invested in Alnylam Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 224 funds opening new positions, 282 increasing their positions, 223 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

357% more first-time investments, than exits

New positions opened: 224 | Existing positions closed: 49

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

37% more capital invested

Capital invested by funds: $43.1B → $59.2B (+$16.1B)

26% more repeat investments, than reductions

Existing positions increased: 282 | Existing positions reduced: 223

26% more funds holding

Funds holding: 653 → 821 (+168)

2.24% less ownership

Funds ownership: 101.33% → 99.09% (-2.2%)

13% less call options, than puts

Call options by funds: $562M | Put options by funds: $649M

Holders
821
Holders Change
+168
Holders Change %
+25.73%
% of All Funds
10.77%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.17%
New
224
Increased
282
Reduced
223
Closed
49
Calls
$562M
Puts
$649M
Net Calls
-$86.5M
Net Calls Change
-$71M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$1.01B
2
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$483M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$391M
4
Jane Street
Jane Street
New York
+$381M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$330M

Top Sellers

Rank Fund Capital Flow
1
RP
Regeneron Pharmaceuticals
New York
-$1.24B
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$858M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$548M
4
Winslow Capital Management
Winslow Capital Management
Minnesota
-$479M
5
Dodge & Cox
Dodge & Cox
California
-$357M
Name Holding Trade Value Shares
Change 		Change in
Stake
PHS
826
PFM Health Sciences
California
– -$23.6M -72,220 Closed
CM
827
Cercano Management
Washington
– -$18.6M -56,953 Closed
IC
828
Ikarian Capital
Texas
– -$18.5M -56,594 Closed
ITP
829
Iron Triangle Partners
Connecticut
– -$9.57M -29,339 Closed
CCM
830
Cinctive Capital Management
New York
– -$7.46M -22,868 Closed
BFM
831
Boothbay Fund Management
New York
– -$6.27M -19,213 Closed
FTM
832
First Turn Management
California
– -$5.83M -17,879 Closed
MASUI
833
MIRAE ASSET SECURITIES (USA) INC.
New York
– -$4.25M -13,034 Closed
RAM
834
Readystate Asset Management
Illinois
– -$3.78M -11,601 Closed
PSC
835
Portman Square Capital
United Kingdom
– -$2.84M -6,967 Closed
SGH
836
Sivik Global Healthcare
Connecticut
– -$2.12M -6,500 Closed
HSA
837
Hussman Strategic Advisors
Maryland
– -$2.05M -6,300 Closed
VSQM
838
V-Square Quantitative Management
Illinois
– -$552K -1,692 Closed
WSFS
839
Wilmington Savings Fund Society
Delaware
– -$550K -1,686 Closed
EMCIP
840
Ewing Morris & Co Investment Partners
Ontario, Canada
– -$470K -1,440 Closed
BS
841
Banco Santander
Spain
– -$406K -1,245 Closed
QIM
842
Quantitative Investment Management
Virginia
– -$403K -1,238 Closed
Group One Trading
843
Group One Trading
Illinois
– -$462K -1,134 Closed
JAM
844
Jupiter Asset Management
United Kingdom
– -$318K -974 Closed
FIM
845
Freedom Investment Management
Connecticut
– -$305K -934 Closed
NRD
846
Nebula Research & Development
New York
– -$293K -900 Closed
IC
847
Iconiq Capital
California
– -$263K -806 Closed
SFC
848
Strategic Financial Concepts
Texas
– -$245K -750 Closed
GS
849
GTS Securities
New York
– -$244K -747 Closed
FTUS
850
Flow Traders U.S.
New York
– -$241K -740 Closed
31 32 33
34
35

ALNY Hedge Fund Activity: Q3 2025 in Review

821 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2025, worth a combined $59.2B — up 37% from $43.1B a quarter earlier.

Buyers outnumbered sellers: 224 funds opened new ALNY positions and 49 closed out — a net gain of 175 holders — while 282 added to existing stakes and 223 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $1.01B. The largest seller was Regeneron Pharmaceuticals, cutting an estimated $1.24B.

  • 821 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2025, up from 653 in Q2 2025.
  • Funds reported $59.2B of Alnylam Pharmaceuticals stock for Q3 2025, up 37% quarter-over-quarter.
  • 224 funds opened new Alnylam Pharmaceuticals positions in Q3 2025 and 49 closed out, a net change of +175 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q3 2025 was JP Morgan Chase, an estimated $1.01B added.
  • The largest Alnylam Pharmaceuticals seller in Q3 2025 was Regeneron Pharmaceuticals, an estimated $1.24B sold.

Based on aggregated 13F filings for Q3 2025.